Drug Trial Radar · NCT02910219
Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients
Last checked: Nov 20, 2026Latest source record: Oct 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Jan 31, 2017
Primary completion
Nov 23, 2020
Study completion Nov 23, 2020
Sponsor
- Lead sponsor
- Sandra SwainAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Lombardi Comprehensive Cancer Center; Medstar Health Research Institute; Genentech, Inc.; Napo Pharmaceuticals, Inc.
- First posted
- Sep 21, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chemotherapy induced diarrhea is seen in up to 40-80% of patients receiving this treatment for HER2 positive locally advanced or metastatic breast cancer. This diarrhea can significantly impact a patient's quality of life and ability to tolerate chemo/anti-HER2 therapy. This study will look at the efficacy of the drug crofelemer in preventing diarrhea in breast cancer patients.
Conditions
- Breast Cancer
Interventions
CrofelemerDrug
Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diarrhea for >= 2 Consecutive DaysTime frame: Cycle 1, Cycle 2 (each cycle is 21 days)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia
MedStar Franklin Square Cancer Center at Loch Raven Campus
Baltimore, Maryland
Harry and Jeanette Weinberg Cancer Institute
Baltimore, Maryland
John Theurer Cancer Center at Hackensack Univ
Hackensack, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.